Bags FDA Approval for a Landmark Advancement in Cardiovascular and Diabetes Care
Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for Rybelsus® (oral semaglutide), marking a groundbreaking milestone in diabetes and cardiovascular care. Rybelsus® becomes the first-ever GLP-1 (glucagon-like peptide-1) receptor agonist in oral form to be approved for reducing the risk of major adverse cardiovascular events (MACE)—including heart attack, stroke, and cardiovascular (CV) death, in adults with type 2 diabetes, regardless of prior cardiovascular disease history.
This approval reinforces Novo Nordisk’s leadership in advancing innovative therapies that go beyond glycemic control to address broader health risks in diabetic populations. By expanding the use of oral semaglutide beyond glucose regulation, the company aims to redefine preventive cardiovascular treatment strategies for millions of patients globally.
The Significance of the Approval
The newly approved indication positions Rybelsus® as a key therapy for both primary and secondary prevention of cardiovascular events.
● Primary prevention focuses on managing and lowering risk factors among adults at high risk for cardiovascular complications.
● Secondary prevention targets individuals with existing cardiovascular disease, helping to mitigate further incidents such as heart attack or stroke.
This expanded use underscores the therapeutic versatility of semaglutide, a molecule already recognized for its robust metabolic and cardiovascular benefits.
In addition, Novo Nordisk has submitted a supplemental New Drug Application (sNDA) in the United States for an oral formulation of semaglutide (once-daily) under the brand name Wegovy®, targeting the treatment of obesity. If approved, this could further extend semaglutide’s reach into weight management and metabolic care.
Insights from the SOUL Clinical Trial
The FDA’s decision is strongly supported by findings from the Phase 3b SOUL trial, which evaluated the cardiovascular outcomes of oral semaglutide (14 mg) alongside standard care in adults with type 2 diabetes at high cardiovascular risk.
The primary endpoint was the time to the first occurrence of a MACE, defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke.
Results demonstrated:
● MACE occurred in 12.0% (579/4,825) of participants treated with semaglutide, compared to 13.8% (668/4,825) in the placebo group.
● This translates to a statistically significant 14% relative risk reduction in MACE over a four-year period, emphasizing the meaningful cardiovascular protection offered by oral semaglutide.
These findings add to a growing body of evidence from real-world data and large-scale randomized clinical trials, establishing semaglutide as a cornerstone molecule with proven efficacy across multiple therapeutic areas, including diabetes, cardiovascular health, and weight management.
Statements from Novo Nordisk Leadership
Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc., expressed pride in this pivotal achievement:
“Being the only FDA-approved GLP-1 therapy available in a pill form, Rybelsus® has now been recognized for its evident cardiovascular benefits. This marks a new milestone for the future of our oral innovation platform. The semaglutide molecule continues to demonstrate consistent and comprehensive clinical outcomes across multiple large-scale trials, reinforcing its role in improving long-term health for patients.”
Broader Implications for Patient Care
The approval of Rybelsus® for cardiovascular risk reduction represents a significant advancement in the management of type 2 diabetes, where cardiovascular disease remains one of the leading causes of mortality. Oral semaglutide’s unique administration form addresses challenges with injectable GLP-1 therapies, potentially improving patient adherence and accessibility.
With cardiovascular protection now added to its benefits, Rybelsus® strengthens Novo Nordisk’s growing portfolio of semaglutide-based therapies, aligning with the company’s mission to defeat diabetes and chronic disease through innovative science and patient-centric care.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
About the Author
